Research Analysts Issue Forecasts for AQST FY2025 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($0.65) for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the business posted ($0.03) EPS.

A number of other equities analysts also recently commented on the company. Leerink Partners lifted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities reissued a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus price target of $11.00.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $3.13 on Wednesday. The firm has a market cap of $285.39 million, a P/E ratio of -6.96 and a beta of 2.71. The firm has a fifty day moving average of $3.86 and a two-hundred day moving average of $4.19. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Janney Montgomery Scott LLC increased its holdings in shares of Aquestive Therapeutics by 6.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after acquiring an additional 61,200 shares during the period. SG Americas Securities LLC raised its holdings in shares of Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after buying an additional 7,347 shares during the last quarter. Barclays PLC boosted its position in shares of Aquestive Therapeutics by 285.4% during the third quarter. Barclays PLC now owns 99,312 shares of the company’s stock worth $495,000 after buying an additional 73,542 shares during the period. Geode Capital Management LLC grew its holdings in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after buying an additional 90,543 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at approximately $922,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.